Current status of therapy for breast cancer worldwide and in Japan

Figure 10 Phase III trial of pegylated liposomal doxorubicin HCL vs conventional doxorubicin for first-line treatment of metastatic breast cancer. A: Relapse-free survival (RFS). [6.9 mo vs 7.8 mo, hazard ratio = 1.00, 95% CI: 0.82-1.22]. PLD: Pegylated liposomal doxorubicin. (Source: Figure 1 in reference 11); B: Overall survival (OS). (21 mo vs 22 mo, HR = 0.94, 95% CI: 0.74-1.19). (Source: Figure 4 in reference 11).